Loading
A phase 2 trial of Enzalutamide in prostate cancer, run by Syntrix Biosystems, Inc., now recruiting.
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06228053 by Syntrix Biosystems, Inc., with 53 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-06-30. Interventions recorded: SX-682, Enzalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/